Cogent Biosciences, Inc.
COGT
Pozycja w akcjach
#3232
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted... Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.
Cena akcji
$31.49
Ostatnia synchronizacja: 2026-10-21
Kapitalizacja rynkowa
$5.46B
Zmiana (1 dzień)
0.81%
Zmiana (1 rok)
112.08%
Kraj
US
Handel Cogent Biosciences, Inc. (COGT)
Kategoria
Healthcare
Historia ceny akcji dla Cogent Biosciences, Inc. (COGT)
Najwyższa cena zamknięcia: $30.19 dnia 2026-10-01
Najniższa cena zamknięcia: $44.44 dnia 2018-03-01
Najniższa cena zamknięcia: $44.44 dnia 2018-03-01
Historia cen akcji firmy Cogent Biosciences, Inc. od 2018 do 2026
Roczna wydajność ceny akcji
| Rok | Wydajność |
|---|---|
| 2026 (TTM) | -10.69% |
| 2025 | 364.44% |
| 2024 | 37.29% |
| 2023 | -46.89% |
| 2022 | 39.37% |
| 2021 | -29.74% |
| 2020 | 349.09% |
| 2019 | -87.13% |
| 2018 | 0.00% |
Cena akcji podobnych firm lub konkurencji
| Firma | Cena akcji | Zmiana 1r% | Kraj |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.95 | -3.70% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $752.87 | 7.01% |
CH
|
